The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. That said, here are two stocks where Wall Street’s excitement appears well-founded and one where consensus estimates seem disconnected from reality.
One Stock to Sell:
Fortrea (FTRE)
Consensus Price Target: $12.66 (22.5% implied return)
Spun off from Labcorp in 2023 to focus exclusively on clinical research services, Fortrea (NASDAQ: FTRE) is a contract research organization that helps pharmaceutical, biotech, and medical device companies develop and bring their products to market through clinical trials and support services.
Why Should You Sell FTRE?
- Products and services are facing significant end-market challenges during this cycle as sales have declined by 2.9% annually over the last four years
- Negative returns on capital show management lost money while trying to expand the business, and its falling returns suggest its earlier profit pools are drying up
- Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results
Fortrea is trading at $10.34 per share, or 14.7x forward P/E. To fully understand why you should be careful with FTRE, check out our full research report (it’s free).
Two Stocks to Watch:
TaskUs (TASK)
Consensus Price Target: $12 (64.6% implied return)
Starting as a virtual assistant service in 2008 before evolving into a global digital services provider, TaskUs (NASDAQ: TASK) provides outsourced digital services including customer experience management, content moderation, and AI data services to innovative technology companies.
Why Do We Like TASK?
- Annual revenue growth of 19.9% over the past five years was outstanding, reflecting market share gains this cycle
- Free cash flow margin grew by 18.3 percentage points over the last five years, giving the company more chips to play with
- Rising returns on capital show the company is starting to reap the benefits of its past investments
TaskUs’s stock price of $7.29 implies a valuation ratio of 5.2x forward P/E. Is now the time to initiate a position? See for yourself in our full research report, it’s free.
Morningstar (MORN)
Consensus Price Target: $250 (32.9% implied return)
Founded in 1984 by Joe Mansueto with just $80,000 in personal savings, Morningstar (NASDAQ: MORN) provides independent investment data, research, and analysis tools that help investors, advisors, and institutions make informed financial decisions.
Why Is MORN a Top Pick?
- Solid 12% annual revenue growth over the last five years indicates its offering’s solve complex business issues
- Share repurchases have amplified shareholder returns as its annual earnings per share growth of 64.7% exceeded its revenue gains over the last two years
- Industry-leading 16.1% return on equity demonstrates management’s skill in finding high-return investments
At $188.14 per share, Morningstar trades at 16.4x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
